-
公开(公告)号:US20130059834A1
公开(公告)日:2013-03-07
申请号:US13600863
申请日:2012-08-31
申请人: Shaoqing Chen , Javier de Vicente Fidalgo , Matthew Michael Hamilton , Johannes Cornelius Hermann , Joshua Kennedy-Smith , Hongju Li , Allen John Lovey , Matthew C. Lucas , Kin-Chun Thomas Luk , Stephen M. Lynch , Counde O'yang , Fernando Padilla , Ryan Craig Schoenfeld , Achyutharao Sidduri , Michael Soth , Ce Wang , Peter Michael Wovkulich , Xiaohu Zhang
发明人: Shaoqing Chen , Javier de Vicente Fidalgo , Matthew Michael Hamilton , Johannes Cornelius Hermann , Joshua Kennedy-Smith , Hongju Li , Allen John Lovey , Matthew C. Lucas , Kin-Chun Thomas Luk , Stephen M. Lynch , Counde O'yang , Fernando Padilla , Ryan Craig Schoenfeld , Achyutharao Sidduri , Michael Soth , Ce Wang , Peter Michael Wovkulich , Xiaohu Zhang
IPC分类号: A61K31/4985 , C07D491/107 , A61K31/5377 , C07D471/04 , C07D495/04 , A61P29/00 , A61P31/00 , A61P37/02 , A61P37/06 , A61P9/00 , A61P3/10 , A61P19/02 , A61P11/06 , A61P25/00 , A61P25/28 , A61P17/06 , A61P17/00 , A61P35/00 , A61P35/02 , A61P1/04 , C07D487/04
CPC分类号: C07D487/04
摘要: The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.
摘要翻译: 本发明涉及式I的新型吡咯并吡嗪衍生物的用途,其中所述变量如本文所述定义,其抑制JAK和SYK并且可用于治疗自身免疫和炎性疾病。
-
公开(公告)号:US08314135B2
公开(公告)日:2012-11-20
申请号:US12702673
申请日:2010-02-09
申请人: Yao-Ling Qiu , Ce Wang , Lu Ying , Xiaowen Peng , Yat Sun Or
发明人: Yao-Ling Qiu , Ce Wang , Lu Ying , Xiaowen Peng , Yat Sun Or
IPC分类号: A61K31/4184 , C07D235/08 , C07D235/14
CPC分类号: C07D403/14 , A61K31/4184 , A61K31/427 , A61K31/444 , A61K31/46 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/695 , A61K38/21 , A61K45/06 , C07D401/14 , C07D413/14 , C07D451/02 , C07F9/65583 , A61K2300/00
摘要: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译: 本发明公开了式(I)化合物或其药学上可接受的盐,酯或前药:其抑制含RNA病毒,特别是丙型肝炎病毒(HCV)。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号:US08163707B2
公开(公告)日:2012-04-24
申请号:US12557850
申请日:2009-09-11
申请人: Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
发明人: Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
摘要: The present invention discloses compounds of formula (I), or its β-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.
摘要翻译: 本发明公开了式(I)化合物或其对映异构体或其药学上可接受的盐,酯,立体异构体,互变异构体,溶剂合物,前药或其组合:其抑制,预防或治疗异常细胞增殖和/ 或病毒感染,特别是HIV,HCV或HBV。 因此,本发明的化合物干扰病毒的复制循环,也可用作抗病毒剂,或干扰宿主细胞生物化学过程,也可用作抗增殖剂。 本发明还涉及药物组合物,其包含用于给患有病毒感染和/或细胞增殖的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的病毒感染和/或细胞增殖的方法。 本发明涉及上文所述的新的抗病毒/抗增殖化合物,包含这些化合物的药物组合物,以及用于治疗或预防需要用所述化合物治疗的受试者的病毒感染的方法。
-
公开(公告)号:US20120076756A1
公开(公告)日:2012-03-29
申请号:US13252924
申请日:2011-10-04
申请人: Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
发明人: Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
IPC分类号: A61K38/21 , A61K31/4184 , C07D401/14 , A61K31/444 , C07D405/14 , A61K31/4545 , C07D413/14 , A61K31/5377 , A61K31/496 , C07D409/14 , C07F9/6558 , A61K31/675 , A61K31/506 , C07D403/10 , A61K39/12 , A61K31/7056 , A61K31/427 , A61P31/14 , A61P31/18 , C07D403/14
CPC分类号: C07D403/14 , A61K31/41 , A61K31/4184 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/675 , A61K31/7056 , A61K38/19 , A61K38/21 , A61K38/212 , A61K38/215 , A61K38/217 , A61K39/00 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/08 , C07F9/65583 , A61K2300/00 , A61K39/12
摘要: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译: 本发明公开了式(I)化合物或其药学上可接受的盐,酯或前药:其抑制含RNA病毒,特别是丙型肝炎病毒(HCV)。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号:US20110250172A1
公开(公告)日:2011-10-13
申请号:US13082621
申请日:2011-04-08
申请人: Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Yat Sun Or
发明人: Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Yat Sun Or
IPC分类号: A61K38/21 , A61K31/4188 , A61K31/4439 , A61K31/454 , A61K31/5377 , A61K31/496 , A61K31/427 , A61K31/422 , C12N7/06 , A61K39/12 , A61P31/14 , A61P37/04 , A61P29/00 , A61P31/18 , C07D498/16
CPC分类号: C07D498/18 , A61K31/4188 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K38/21 , A61K38/55 , A61K45/06 , C07D519/00 , C12N2770/24211 , A61K2300/00
摘要: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译: 本发明公开了式(I)化合物或其药学上可接受的盐,酯或前药:其抑制含RNA病毒,特别是丙型肝炎病毒(HCV)。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号:US20110008288A1
公开(公告)日:2011-01-13
申请号:US12816171
申请日:2010-06-15
申请人: Yat Sun Or , Lu Ying , Xiaowen Peng , Datong Tang , Ce Wang , Yao-Ling Qiu
发明人: Yat Sun Or , Lu Ying , Xiaowen Peng , Datong Tang , Ce Wang , Yao-Ling Qiu
IPC分类号: A61K31/437 , C07D471/04 , C07F9/6561 , C07D498/04 , C07D513/04 , A61K31/5377 , A61K31/496 , A61K31/675 , A61K31/4709 , A61K31/506 , A61K39/00 , A61K38/21 , A61K31/7056 , A61P31/14 , C12N7/04
CPC分类号: C07F9/6561 , A61K31/437 , A61K31/4709 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/675 , A61K31/7056 , A61K38/00 , A61K45/06 , C07D471/04 , C07D487/04 , C07D513/04 , C07D519/00 , A61K2300/00
摘要: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号:US20100266543A1
公开(公告)日:2010-10-21
申请号:US12702673
申请日:2010-02-09
申请人: Yao-Ling Qiu , Ce Wang , Lu Ying , Xiaowen Peng , Yat Sun Or
发明人: Yao-Ling Qiu , Ce Wang , Lu Ying , Xiaowen Peng , Yat Sun Or
IPC分类号: A61K38/21 , C07D403/14 , A61K31/4184 , A61P31/14 , A61K39/00 , A61P31/20 , A61P31/18 , A61K31/7056 , A61K31/427 , C07D401/14 , A61K31/444 , C07F7/10 , A61K31/695 , A61K31/496 , A61K38/12 , A61K31/506 , C07D413/14 , A61K31/5377
CPC分类号: C07D403/14 , A61K31/4184 , A61K31/427 , A61K31/444 , A61K31/46 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/695 , A61K38/21 , A61K45/06 , C07D401/14 , C07D413/14 , C07D451/02 , C07F9/65583 , A61K2300/00
摘要: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译: 本发明公开了式(I)化合物或其药学上可接受的盐,酯或前药:其抑制含RNA病毒,特别是丙型肝炎病毒(HCV)。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号:US20100226883A1
公开(公告)日:2010-09-09
申请号:US12707200
申请日:2010-02-17
申请人: Yao-Ling Qiu , Lu Ying , Ce Wang , Xiaowen Peng , Yat Sun Or
发明人: Yao-Ling Qiu , Lu Ying , Ce Wang , Xiaowen Peng , Yat Sun Or
IPC分类号: A61K38/21 , C07D403/14 , A61K31/4178 , C07D401/14 , A61K31/444 , A61K31/4545 , C07D413/14 , A61K31/5377 , A61K38/19 , A61K39/00 , A61K31/7056 , A61K31/427 , A61P1/16 , A61P31/20 , A61P31/18 , A61P31/14
CPC分类号: C07D403/14 , A61K38/21 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07F9/65583 , A61K2300/00
摘要: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译: 本发明公开了式(I)化合物或其药学上可接受的盐,酯或前药:其抑制含RNA病毒,特别是丙型肝炎病毒(HCV)。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号:US20100221214A1
公开(公告)日:2010-09-02
申请号:US12702692
申请日:2010-02-09
申请人: Yat Sun Or , Ce Wang , Xiaowen Peng , Lu Ying , Yao-Ling Qiu
发明人: Yat Sun Or , Ce Wang , Xiaowen Peng , Lu Ying , Yao-Ling Qiu
IPC分类号: A61K31/4184 , C07D403/14 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , A61K31/444 , A61K31/4545 , A61K31/5377 , A61K31/496 , A61P31/14 , A61K38/21 , A61K39/00 , A61K31/427
CPC分类号: A61K31/4184 , A61K31/427 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14
摘要: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译: 本发明公开了式(I)化合物或其药学上可接受的盐,酯或前药:其抑制含RNA病毒,特别是丙型肝炎病毒(HCV)。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号:US20100074889A1
公开(公告)日:2010-03-25
申请号:US12557850
申请日:2009-09-11
申请人: Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
发明人: Yao-Ling Qiu , Ce Wang , Xiaowen Peng , Lu Ying , Yat Sun Or
IPC分类号: C07D239/47 , C07D239/54 , C07F9/02 , A61K31/675 , A61K39/395 , A61K38/48 , C12N7/06 , A61P31/12 , A61P31/18
摘要: The present invention discloses compounds of formula (I), or its β-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.
摘要翻译: 本发明公开了式(I)化合物或其对映体或其药学上可接受的盐,酯,立体异构体,互变异构体,溶剂化物,前药或其组合:其抑制,预防或治疗异常细胞增殖和/ 或病毒感染,特别是HIV,HCV或HBV。 因此,本发明的化合物干扰病毒的复制循环,也可用作抗病毒剂,或干扰宿主细胞生物化学过程,也可用作抗增殖剂。 本发明还涉及药物组合物,其包含用于给患有病毒感染和/或细胞增殖的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的病毒感染和/或细胞增殖的方法。 本发明涉及上文所述的新的抗病毒/抗增殖化合物,包含这些化合物的药物组合物,以及用于治疗或预防需要用所述化合物治疗的受试者的病毒感染的方法。
-
-
-
-
-
-
-
-
-